Antisense oligonucleotides optimized for kidney targeting
US8258105B2 · kind B2 · utility
9Cited by
19References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 21, 2004 |
| Grant date | Sep 4, 2012 |
| Priority date | — |
| Expiry date | Jan 5, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2500/40
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides antisense compounds and methods for modulating the expression of target genes expressed in the kidney. In particular, this invention provides antisense oligonucleotide compounds optimized for targeting nucleic acid molecules expressed in the kidney. Such compounds are shown herein to efficiently modulate the expression of target genes SGLT2 and connective tissue growth factor (CTGF) in the kidney.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.